MSandMeMedia

People who do not have multiple sclerosis can never fully understand what it is like living with MS. What they can show us is empathy. MS & Me Media presents: Empathy #MSAwareness #WeHaveMS @MSPurposeRadio youtu.be/SQIYJ_BTmag

Study Finds High Dose Vitamin D Does Not Reduce Disease Activity in people with Relapsing-Remitting (RR) MS abstractsonline.com/pp8/#!/10822/p… @ACTRIMS

MS Focus is hosting a virtual Q&A event led by Aaron Boster, MD, on Tues., Nov. 22nd, at 6:30 pm EST. @AaronBosterMD is a board-certified Neurologist specializing in MS, making him the perfect person to answer your MS-related questions! Pre-register now: msfocus.us/Boster1122

#Remylenation in #MS. Dr Brown shares about current #research and timescales and how to get involved youtu.be/YMQayl_-xAs

Every time you have a lesion in a nerve pathway, surviving nerves are required to compensate for the damage 🧠 Discover more about MS progression and the best known ways to prevent it, featuring @tripping_onair and @GavinGiovannoni 👉 bit.ly/MSProgression_… #MultipleSclerosis

This study from Oklahoma City Veterans Affairs of 279 PwMS showed that taking medication consistently was associated with lower mortality. "In the good adherence group, patients lived for a median of 52 years [after diagnosis]" Confounded data? multiplesclerosisnewstoday.com/news-posts/202…

Part of having strength is knowing that you can’t be strong all the time. Living with MS is hard. We can fake smiles and push through the pain, but sometimes we break…and that’s OK. We’re only human.

monoclonal antibodies are effective for covid-19 in people taking b-cell depleters (ocrevus, rituximab, kesimpta) based on this observational study (5% of those treated hospitalized vs. 39.2% of those untreated hospitalized per this observational study) pubmed.ncbi.nlm.nih.gov/35791921/

Could EBV vaccines prevent MS in the future? An opinion article. Authors include @GavinGiovannoni and @AlbertoAscherio frontiersin.org/articles/10.33…

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers - PubMed pubmed.ncbi.nlm.nih.gov/35668317/

Tixagevimab and Cilgavimab (Evusheld) is an option for people with MS taking b-cell depleters (kesimpta/ocrevus/rituximab) who have a poor antibody response to covid-19 vaccines (image is pre and post antibody titers). pubmed.ncbi.nlm.nih.gov/35661563/

Aging & MS:New MS Living Well podcast Drs. Weinstock-Guttman & Corboy on #aging well, immune changes & stopping MS meds DMTs. bit.ly/38yZVQK🍎apple.co/3E1YAOd @MS_Stumbling @TheMSKittylady @pettigrew66 @MarkWebb_ @DanJenDig @TwoFacesofMS @GenaMSwarrior @themsguide

@MSPurposeRadio #wehavems #easter #Passover

#ValentinesDay #WeHaveMS @MSPurposeRadio

#NewYear2022 #WeHaveMS @MSPurposeRadio

#WeHaveMS @MSPurposeRadio

Do you remember when you joined Twitter? I do! #MyTwitterAnniversary #WeHaveMS

From our hearts to your homes… @MSPurposeRadio #WeHaveMS

Measuring treatment response to advance precision medicine for multiple sclerosis - PubMed pubmed.ncbi.nlm.nih.gov/34704393/

The availability of 15 subsidised DMTs in Australia has transformed the quality of life of people with MS. 💊 Unfortunately, this is not the case for New Zealanders with MS, who only have access to four DMTs. Read more 👉 ow.ly/oujO50GuiUw #MS #RealMSResearch #VoiceForMS